TL 05
Alternative Names: TL-05Latest Information Update: 28 Jul 2022
At a glance
- Originator Tilos Therapeutics
- Class Anti-inflammatories; Antibodies; Antifibrotics
- Mechanism of Action Immunomodulators; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for research development in Fibrosis in USA (Parenteral)
- 30 Jul 2019 Tilos Therapeutics has been acquired by Merck & Co
- 14 Aug 2018 Tilos Therapeutics plans early proof-of-concept preclinical trials for Fibrosis in USA (Tilos Therapeutics website, August 2018)